{"type":"trials","record":{"id":32142,"source_id":"clinicaltrials-gov","external_id":"NCT03408574","title":"The Nicotinic Cholinergic System and Cognitive Aging","brief_summary":"Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are clear in dementia, what remains uncertain is the role that the cholinergic system in general and a subset of receptors called the nicotinic system plays in cognition in healthy non-demented older adults (referred to as normal cognitive aging). This is critical because the ever growing healthy aging population will show declines in cognition that fall short of dementia but still impact functional abilities and independence. Maintaining good nicotinic system functioning throughout adulthood may lessen the cognitive symptoms of aging. At this time, it is not clear what the biological cause of age-related changes in cognition is. This study will examine the role of the nicotinic system in the healthy aging brain and examine its role in memory and thinking processes in older and younger adults.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"University of Vermont","enrollment":104,"countries":["United States"],"start_date":"2016-10-01","completion_date":"2022-01-31","last_update_date":"2023-05-09","source_url":"https://clinicaltrials.gov/study/NCT03408574","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:16:23.954312+00:00","last_seen_at":"2026-09-25T06:10:45.89+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years to 75 Years","comparator":null,"organization":"University of Vermont","interventions":["Nicotine patch, oral mecamylamine, placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Age effects of nicotinic blockade — After the completion of the third study day.","Age effects of nicotinic stimulation — After the completion of the third study day."],"design_description":"RANDOMIZED · PARALLEL · BASIC SCIENCE · TRIPLE","source_has_results":false},"controlled_terms":["Healthy Aging","Nicotine patch, oral mecamylamine, placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: cognitive aging.","quality_checked_at":"2026-09-25T06:10:48.460085+00:00","duplicate_cluster_key":"id:nct03408574","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2016-10-01 to 2022-01-31","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 75 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:45.910Z","intervention":["Nicotine patch, oral mecamylamine, placebo"],"participants":104,"study_design":"RANDOMIZED · PARALLEL · BASIC SCIENCE · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Age effects of nicotinic blockade — After the completion of the third study day.","Age effects of nicotinic stimulation — After the completion of the third study day."],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"cognitive-aging","is_published":true,"match_reasons":["Title contains controlled term: cognitive aging.","Abstract contains controlled term: cognitive aging.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Cognitive ageing","slug":"cognitive-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/32142","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}